These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 21795848)

  • 21. Cost of atrial fibrillation in United States managed care organizations.
    Kim MH; Lin J; Hussein M; Kreilick C; Battleman D
    Adv Ther; 2009 Sep; 26(9):847-57. PubMed ID: 19768638
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Invasive meningococcal disease--improving management through structured review of cases in the Hunter New England area, Australia.
    Guimont C; Hullick C; Durrheim D; Ryan N; Ferguson J; Massey P
    J Public Health (Oxf); 2010 Mar; 32(1):38-43. PubMed ID: 19638395
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The costs of nonsedating antihistamine therapy for allergic rhinitis in managed care: an updated analysis.
    Liao E; Leahy M; Cummins G
    Am J Manag Care; 2001 Oct; 7(15 Suppl):S459-68. PubMed ID: 11680261
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of leflunomide versus biologic agents on the costs of care for rheumatoid arthritis in a managed care population.
    Ollendorf DA; Peterson AN; Doyle J; Huse DM
    Am J Manag Care; 2002 May; 8(7 Suppl):S203-13. PubMed ID: 12022236
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The direct costs of untreated comorbid insomnia in a managed care population with major depressive disorder.
    Asche CV; Joish VN; Camacho F; Drake CL
    Curr Med Res Opin; 2010 Aug; 26(8):1843-53. PubMed ID: 20515321
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Healthcare utilization and costs of patients with rosacea in an insured population.
    Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
    J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence of other diabetes-associated complications and comorbidities and its impact on health care charges among patients with diabetic neuropathy.
    Zhao Y; Ye W; Boye KS; Holcombe JH; Hall JA; Swindle R
    J Diabetes Complications; 2010; 24(1):9-19. PubMed ID: 18930413
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of patients receiving peritoneal dialysis using health insurance claims data.
    Berger A; Edelsberg J; Inglese G; Bhattacharyya S; Oster G
    Clin Ther; 2009 Jun; 31(6):1321-34. PubMed ID: 19695397
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhaled corticosteroids vs leukotriene receptor antagonists: health care costs across varying asthma severities.
    O'Connor RD; Parasuraman B; Roberts C; Leibman C
    Ann Allergy Asthma Immunol; 2006 Aug; 97(2):236-43. PubMed ID: 16937758
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of comorbid depression or anxiety on patterns of treatment and economic outcomes among patients with diabetic peripheral neuropathic pain.
    Boulanger L; Zhao Y; Foster TS; Fraser K; Bledsoe SL; Russell MW
    Curr Med Res Opin; 2009 Jul; 25(7):1763-73. PubMed ID: 19505204
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer's disease and related dementias enrolled in a large medicare managed care plan: a case-control study.
    Lu S; Hill J; Fillit H
    Am J Geriatr Pharmacother; 2005 Jun; 3(2):92-102. PubMed ID: 16129386
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence and cost of medication nonadherence in Parkinson's disease: evidence from administrative claims data.
    Davis KL; Edin HM; Allen JK
    Mov Disord; 2010 Mar; 25(4):474-80. PubMed ID: 20131374
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Health care utilization and costs of Alzheimer's disease: the role of co-morbid conditions, disease stage, and pharmacotherapy.
    Fillit H; Hill JW; Futterman R
    Fam Med; 2002; 34(7):528-35. PubMed ID: 12144008
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk factors for invasive meningococcal disease in southern Queensland, 2000-2001.
    McCall BJ; Neill AS; Young MM
    Intern Med J; 2004 Aug; 34(8):464-8. PubMed ID: 15317544
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic burden of resected squamous cell carcinoma of the head and neck in a US managed-care population.
    Amonkar MM; Chastek B; Samant N; Teitelbaum A
    J Med Econ; 2011; 14(4):421-32. PubMed ID: 21619455
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Economic burden of rhinitis in managed care: a retrospective claims data analysis.
    Dalal AA; Stanford R; Henry H; Borah B
    Ann Allergy Asthma Immunol; 2008 Jul; 101(1):23-9. PubMed ID: 18681080
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Asthma costs and utilization in a managed care organization.
    Zeiger RS; Hay JW; Contreras R; Chen W; Quinn VP; Seal B; Schatz M
    J Allergy Clin Immunol; 2008 Apr; 121(4):885-92.e5. PubMed ID: 18313133
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Utilization and costs for children who have special health care needs and are enrolled in a hospital-based comprehensive primary care clinic.
    Berman S; Rannie M; Moore L; Elias E; Dryer LJ; Jones MD
    Pediatrics; 2005 Jun; 115(6):e637-42. PubMed ID: 15930189
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lifetime costs of invasive meningococcal disease: A Markov model approach.
    Wang B; Haji Ali Afzali H; Giles L; Marshall H
    Vaccine; 2019 Oct; 37(46):6885-6893. PubMed ID: 31594708
    [TBL] [Abstract][Full Text] [Related]  

  • 40. AMEND study protocol: a case-control study to assess the long-term impact of invasive meningococcal disease in Australian adolescents and young adults.
    Marshall H; McMillan M; Wang B; Booy R; Afzali H; Buttery J; Blyth CC; Richmond P; Shaw D; Gordon D; Barton B
    BMJ Open; 2019 Dec; 9(12):e032583. PubMed ID: 31888931
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.